These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24895641)

  • 1. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, improves hyperglycemia and dyslipidemia independent of suppression of food intake in diabetic rats.
    Sakata S; Ito M; Mera Y; Sasase T; Yamamoto H; Kakutani M; Ohta T
    J Diabetes Res; 2014; 2014():803832. PubMed ID: 24895641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat.
    Sakata S; Mera Y; Kuroki Y; Nashida R; Kakutani M; Ohta T
    J Diabetes Res; 2014; 2014():890639. PubMed ID: 24772450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats.
    Hata T; Mera Y; Kawai T; Ishii Y; Kuroki Y; Kakimoto K; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 Jul; 13(7):629-38. PubMed ID: 21362121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of hypoglycemic effects of an intestine-specific inhibitor of microsomal triglyceride transfer protein (MTP) in obese rats.
    Sakata S; Katsumi S; Mera Y; Kuroki Y; Nashida R; Kakutani M; Ohta T
    J Pharmacol Sci; 2015 Jan; 127(1):103-8. PubMed ID: 25704025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner.
    Hata T; Mera Y; Ishii Y; Tadaki H; Tomimoto D; Kuroki Y; Kawai T; Ohta T; Kakutani M
    J Pharmacol Exp Ther; 2011 Mar; 336(3):850-6. PubMed ID: 21139060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein.
    Mera Y; Odani N; Kawai T; Hata T; Suzuki M; Hagiwara A; Katsushima T; Kakutani M
    J Pharmacol Exp Ther; 2011 Feb; 336(2):321-7. PubMed ID: 20974698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models.
    Mera Y; Kawai T; Ogawa N; Odani N; Sasase T; Miyajima K; Ohta T; Kakutani M
    J Pharmacol Sci; 2015 Nov; 129(3):169-76. PubMed ID: 26598005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, reduces food preference for fat.
    Mera Y; Hata T; Ishii Y; Tomimoto D; Kawai T; Ohta T; Kakutani M
    J Diabetes Res; 2014; 2014():583752. PubMed ID: 24959597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily inhibition of postprandial hyperglycaemia with JTT-608, a novel oral antidiabetic agent, ameliorates pancreatic function in neonatally streptozotocin-treated rats.
    Ohta T; Sasase T; Miyajima K; Matsui K; Matsushita M; Furukawa N; Yonemori F
    Diabetes Obes Metab; 2005 Sep; 7(5):517-24. PubMed ID: 16050944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells.
    Chen FF; Wang JT; Zhang LX; Xing SF; Wang YX; Wang K; Deng SL; Zhang JQ; Tang L; Wu HS
    Br J Pharmacol; 2017 Sep; 174(17):2912-2928. PubMed ID: 28627773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent intermittent restraint delays fed and fasting hyperglycemia and improves glucose return to baseline levels during glucose tolerance tests in the Zucker diabetic fatty rat--role of food intake and corticosterone.
    Bates HE; Kiraly MA; Yue JT; Goche Montes D; Elliott ME; Riddell MC; Matthews SG; Vranic M
    Metabolism; 2007 Aug; 56(8):1065-75. PubMed ID: 17618951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
    Shibata T; Takeuchi S; Yokota S; Kakimoto K; Yonemori F; Wakitani K
    Br J Pharmacol; 2000 Jun; 130(3):495-504. PubMed ID: 10821776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.
    Shibata T; Matsui K; Yonemori F; Wakitani K
    Br J Pharmacol; 1998 Dec; 125(8):1744-50. PubMed ID: 9886766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JTT-501, a new oral hypoglycemic agent, reverses hypertriglyceridemia in Zucker fatty and ventromedial hypothalamus-lesioned obese rats.
    Yamazaki Y; Osaka T; Murakami T; Inoue S
    Metabolism; 2000 May; 49(5):574-8. PubMed ID: 10831165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
    Smith SA; Lister CA; Toseland CD; Buckingham RE
    Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
    Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Bahekar R; Jain M
    Biomed Pharmacother; 2018 Feb; 98():364-371. PubMed ID: 29275178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia.
    Chou WL
    Pharmacol Res; 2021 Aug; 170():105693. PubMed ID: 34048925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
    Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
    Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes.
    Kim KS; Oh DH; Kim JY; Lee BG; You JS; Chang KJ; Chung HJ; Yoo MC; Yang HI; Kang JH; Hwang YC; Ahn KJ; Chung HY; Jeong IK
    Exp Mol Med; 2012 Nov; 44(11):665-73. PubMed ID: 23114424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.